UBS Group’s LAVA Medtech Acquisition Corp. Unit LVACU Stock Holding History

UBS Group’s Portfolio LVACU Stock Details LVACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-181	Closed	-$1.85K	–	11638
2022 Q4	$1.85K	Hold	181	–	–	﹤0.01%	9781
2022 Q3	$2K	Hold	181	–	–	﹤0.01%	9898
2022 Q2	$2K	Hold	181	–	–	﹤0.01%	9778
2022 Q1	$2K	Hold	181	–	–	﹤0.01%	9823
2021 Q4	$2K	Buy	+181	New	+$1.83K	﹤0.01%	9938

Other funds holding LVACU

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

UBS Group's LVACU Position: Q1 2023 in Review

UBS Group sold out of LAVA Medtech Acquisition Corp. Unit (LVACU) in Q1 2023, closing a stake of 181 shares — an estimated $1.85K sold.

UBS Group first reported a position in LVACU in Q4 2021 and held it in 5 quarters. The position peaked at $2K in Q3 2022. 4 funds tracked by Wall St. Rank hold LVACU as of Q1 2023.

UBS Group reported no remaining LAVA Medtech Acquisition Corp. Unit position as of Q1 2023 after selling out during the quarter.
UBS Group sold 181 LAVA Medtech Acquisition Corp. Unit shares in Q1 2023, an estimated $1.85K.
UBS Group first reported a position in LAVA Medtech Acquisition Corp. Unit in Q4 2021 and held it in 5 quarters.
UBS Group's LAVA Medtech Acquisition Corp. Unit position peaked at $2K in Q3 2022.
4 funds tracked by Wall St. Rank held LAVA Medtech Acquisition Corp. Unit as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.